257 reports of this reaction
2.7% of all RAMUCIRUMAB reports
#4 most reported adverse reaction
FEBRILE NEUTROPENIA is the #4 most commonly reported adverse reaction for RAMUCIRUMAB, manufactured by Eli Lilly and Company. There are 257 FDA adverse event reports linking RAMUCIRUMAB to FEBRILE NEUTROPENIA. This represents approximately 2.7% of all 9,650 adverse event reports for this drug.
Patients taking RAMUCIRUMAB who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for RAMUCIRUMAB, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for RAMUCIRUMAB:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 257 FDA reports for RAMUCIRUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 2.7% of all adverse event reports for RAMUCIRUMAB, making it a notable side effect.
If you experience febrile neutropenia while taking RAMUCIRUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.